UNIGE document Scientific Article
previous document  unige:72698  next document
add to browser collection

Sildenafil for the treatment of pulmonary hypertension in children

Merali, Sausan
Published in Expert Review of Cardiovascular Therapy. 2014, vol. 12, no. 10, p. 1157-84
Abstract Pulmonary hypertension, including pulmonary arterial hypertension (PAH), is a serious disease in children, but few clinical studies have been conducted to evaluate treatment regimens in this population. Currently, treatment of children with PAH is mostly based on clinical studies conducted in adults and a few dedicated pediatric studies. Sildenafil, a phosphodiesterase type 5 inhibitor, has an established efficacy and safety profile for the treatment of adults with PAH. In May 2011, sildenafil received approval for the treatment of pediatric patients aged 1-17 years in the EU; however, pediatric use is not approved in the USA. This systematic literature review summarizes the clinical data available on the use of sildenafil to treat children with PAH and pulmonary hypertension.
PMID: 25223406
Full text
Article (Published version) (616 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group L'hypertension pulmonaire (pédiatrie) (228)
(ISO format)
BEGHETTI, Maurice, WACKER BOU PUIGDESABREGAS, Julie Caroline, MERALI, Sausan. Sildenafil for the treatment of pulmonary hypertension in children. In: Expert Review of Cardiovascular Therapy, 2014, vol. 12, n° 10, p. 1157-84. doi: 10.1586/14779072.2014.958077 https://archive-ouverte.unige.ch/unige:72698

316 hits

1 download


Deposited on : 2015-05-19

Export document
Format :
Citation style :